


## Not all **ADTs for prostate** cancer are the same<sup>1,2</sup>

• FIRMAGON® is the only GnRH antagonist available in Australia for the treatment of prostate cancer³

FIRMAGON® is the only ADT that reduces testosterone levels to ≤0.5 ng/mL after the first 3 days on treatment\*1,2

\* Percentage of patients attaining T≤0.5 ng/mL by day 3 of treatment with FIRMAGON 240/80 mg s.c. = 96% and with Leuprorelin 7.5 mg i.m. = 0%¹



Please review Product Information before prescribing. Product Information is available at www.ferring.com.au/products.html

Minimum Product Information: FIRMAGON® degarelix (as acetate). Powder and solvent for injection, depot, 120 and 80mg. INDICATIONS: Treatment of prostate cancer where androgen deprivation is warranted. DOSAGE AND ADMINISTRATION: Start with 240mg s.c. (two 120mg injections at a concentration of 40mg/mL), followed by monthly maintenance dose of 80mg s.c. (one injection at a concentration of 20mg/mL). Vary injection site. Do not rub or massage injection site. CONTRAINDICATIONS: Hypersensitivity to degarelix, excipients or any other GnRH antagonists. Women and children. PRECAUTIONS: QT prolongation; hypersensitivity; changes in bone density; changes in hepatic enzyme measurements; route of administration — do not give IV; severe renal or hepatic impairment; use only as first line ADT. ADVERSE EFFECTS: hot flushes; weight increase; injection site adverse events; liver transaminases increase; weight increase; hypertension; back pain; chills; arthralgia; urinary tract infection; constipation and fatigue. Please review full Product Information before prescribing — PI available from Ferring Pharmaceuticals. #27110-v3.

References: 1. Klotz L et al. BJU Int 2008; 102:1531-1538. 2. FIRMAGON® Product Information. 3. The Pharmaceutical Benefits Scheme (PBS) Website https://www.pbs.giv.au/medicine/item/2784m-2785n [Accessed 15 March 2022].

